XLO PE Ratio & Valuation,Is XLO Overvalued

XLO Relative Valuation

XLO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XLO is overvalued; if below, it's undervalued.

Historical Valuation

Xilio Therapeutics Inc (XLO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.37 is considered Undervalued compared with the five-year average of -1.38. The fair price of Xilio Therapeutics Inc (XLO) is between 1.11 to 1.81 according to relative valuation methord. Compared to the current price of 0.68 USD , Xilio Therapeutics Inc is Undervalued By 38.63%.

Relative Value

Fair Zone

1.11-1.81

Current Price：0.68

38.63%

Undervalued

-1.24

0.00

EV/EBITDA

Xilio Therapeutics Inc. (XLO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.18. The thresholds are as follows: Strongly Undervalued below -3.58, Undervalued between -3.58 and -1.88, Fairly Valued between 1.52 and -1.88, Overvalued between 1.52 and 3.23, and Strongly Overvalued above 3.23. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

1.15

EV/EBIT

Xilio Therapeutics Inc. (XLO) has a current EV/EBIT of 1.15. The 5-year average EV/EBIT is -0.18. The thresholds are as follows: Strongly Undervalued below -3.82, Undervalued between -3.82 and -2.00, Fairly Valued between 1.65 and -2.00, Overvalued between 1.65 and 3.47, and Strongly Overvalued above 3.47. The current Forward EV/EBIT of 1.15 falls within the Historic Trend Line -Fairly Valued range.

1.37

Xilio Therapeutics Inc. (XLO) has a current PS of 1.37. The 5-year average PS is 1.19. The thresholds are as follows: Strongly Undervalued below -2.35, Undervalued between -2.35 and -0.58, Fairly Valued between 2.97 and -0.58, Overvalued between 2.97 and 4.74, and Strongly Overvalued above 4.74. The current Forward PS of 1.37 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Xilio Therapeutics Inc. (XLO) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.34. The thresholds are as follows: Strongly Undervalued below -15.58, Undervalued between -15.58 and -8.96, Fairly Valued between 4.29 and -8.96, Overvalued between 4.29 and 10.91, and Strongly Overvalued above 10.91. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Xilio Therapeutics Inc. (XLO) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.62. The thresholds are as follows: Strongly Undervalued below -2.93, Undervalued between -2.93 and -1.77, Fairly Valued between 0.54 and -1.77, Overvalued between 0.54 and 1.70, and Strongly Overvalued above 1.70. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Xilio Therapeutics Inc (XLO) has a current Price-to-Book (P/B) ratio of -4.36. Compared to its 3-year average P/B ratio of 1.22 , the current P/B ratio is approximately -457.35% higher. Relative to its 5-year average P/B ratio of 1.07, the current P/B ratio is about -506.13% higher. Xilio Therapeutics Inc (XLO) has a Forward Free Cash Flow (FCF) yield of approximately -49.16%. Compared to its 3-year average FCF yield of -104.26%, the current FCF yield is approximately -52.85% lower. Relative to its 5-year average FCF yield of -95.17% , the current FCF yield is about -48.34% lower.

-4.36

P/B

Median3y

1.22

Median5y

1.07

-49.16

FCF Yield

Median3y

-104.26

Median5y

-95.17

Competitors Valuation Multiple

The average P/S ratio for XLO's competitors is 13.24, providing a benchmark for relative valuation. Xilio Therapeutics Inc Corp (XLO) exhibits a P/S ratio of 1.37, which is -89.64% above the industry average. Given its robust revenue growth of 742.51%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of XLO decreased by 28.68% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.26M to 19.07M.

The secondary factor is the Margin Expansion, contributed -86.21%to the performance.

Overall, the performance of XLO in the past 1 year is driven by Revenue Growth. Which is more sustainable.

742.51%

2.26M → 19.07M

Revenue Growth

-86.21%

-619.53 → -85.42

Margin Expansion

-684.98%

0.10 → -0.60

P/E Change

-28.68%

0.96 → 0.68

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Xilio Therapeutics Inc (XLO) currently overvalued or undervalued?

What is Xilio Therapeutics Inc (XLO) fair value?

XLO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Xilio Therapeutics Inc (XLO) is between 1.11 to 1.81 according to relative valuation methord.

How does XLO's valuation metrics compare to the industry average?

What is the current P/B ratio for Xilio Therapeutics Inc (XLO) as of Dec 15 2025?

As of Dec 15 2025, Xilio Therapeutics Inc (XLO) has a P/B ratio of -4.36. This indicates that the market values XLO at -4.36 times its book value.

What is the current FCF Yield for Xilio Therapeutics Inc (XLO) as of Dec 15 2025?

As of Dec 15 2025, Xilio Therapeutics Inc (XLO) has a FCF Yield of -49.16%. This means that for every dollar of Xilio Therapeutics Inc’s market capitalization, the company generates -49.16 cents in free cash flow.

What is the current Forward P/E ratio for Xilio Therapeutics Inc (XLO) as of Dec 15 2025?

As of Dec 15 2025, Xilio Therapeutics Inc (XLO) has a Forward P/E ratio of -1.24. This means the market is willing to pay $-1.24 for every dollar of Xilio Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Xilio Therapeutics Inc (XLO) as of Dec 15 2025?

As of Dec 15 2025, Xilio Therapeutics Inc (XLO) has a Forward P/S ratio of 1.37. This means the market is valuing XLO at $1.37 for every dollar of expected revenue over the next 12 months.

XLO Valuation

XLO Valuation

XLO Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is Xilio Therapeutics Inc (XLO) currently overvalued or undervalued?

What is Xilio Therapeutics Inc (XLO) fair value?

How does XLO's valuation metrics compare to the industry average?

What is the current P/B ratio for Xilio Therapeutics Inc (XLO) as of Dec 15 2025?

What is the current FCF Yield for Xilio Therapeutics Inc (XLO) as of Dec 15 2025?

What is the current Forward P/E ratio for Xilio Therapeutics Inc (XLO) as of Dec 15 2025?

What is the current Forward P/S ratio for Xilio Therapeutics Inc (XLO) as of Dec 15 2025?